Welcome to Haynes Boone’s Biotech Insights! This newsletter is your go-to resource for staying informed on the latest legal developments in biotechnology. Each edition will feature expert analysis of key topics impacting the biotechnology industry, a spotlight on one of our talented team members and details about where to connect with our team at upcoming industry events. We are committed to keeping you informed in this important and rapidly evolving field. This edition features:
Generic drug makers may have some breathing room after the U.S. Supreme Court’s unanimous decision in Hikma v. Amarin, but the skinny-label landscape remains unsettled. The Court held that Amarin had not sufficiently pleaded that Hikma’s generic Vascepa label, website statements and press releases actively induced infringement of Amarin’s cardiovascular indication patents. Still, the case has been remanded, and the line between lawful carve-outs and alleged inducement remains commercially important. This article breaks down what the decision means for skinny labels, method-of-use patents and the risks generic manufacturers must manage when launching around protected indications.
Early-Stage Funding for Life Sciences Businesses
As life science companies move from discovery to development, choosing the right funding instrument is far from straightforward. Equity issuances, SAFEs, promissory notes and convertible notes each carry distinct legal and financial consequences, and the wrong structure can mean unexpected dilution, misaligned investor incentives or repayment obligations the company cannot meet. Misjudging these trade-offs early on can constrain a company's options for years. This article breaks down how each instrument works and what founders need to consider before their next capital raise.
Read the full Summer 2026 Biotech Insights here.
